Active ingredient: Gemfibrozil

Form/Route: Tablets/Oral

Recommended studies: 1 study

1. Type of study: Fasting
   Design: Single-dose, two-way, crossover in-vivo
   Strength: 600 mg
   Subjects: Healthy males and nonpregnant females, general population.

Additional Comments:

Analytes to measure (in appropriate biological matrix): Gemfibrozil in plasma.

Bioequivalence based on (90% CI): Gemfibrozil

Waiver request of in-vivo testing: Not applicable.

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Dec 2009